---
title: "Understanding the Market | AKESO rises over 8% as the results of the HARMONi-6 study will be published simultaneously in The Lancet and ESMO LBA"
description: "Akeso's stock price rose by more than 8%, with an increase of 6.97% as of the time of writing, reported at HKD 130.5, with a transaction volume of HKD 749 million. The company announced that the resul"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261354820.md"
published_at: "2025-10-16T02:28:03.000Z"
---

# Understanding the Market | AKESO rises over 8% as the results of the HARMONi-6 study will be published simultaneously in The Lancet and ESMO LBA

> Akeso's stock price rose by more than 8%, with an increase of 6.97% as of the time of writing, reported at HKD 130.5, with a transaction volume of HKD 749 million. The company announced that the results of the Phase III clinical study of its dual-specific antibody new drug, Ivorocimab, will be published in 2025 in The Lancet and at the European Society for Medical Oncology (ESMO) conference, with a verbal presentation by Professor Lu Shun, showcasing its comparative results with PD-1 combined chemotherapy

According to Zhitong Finance APP, AKESO (09926) rose over 8%, and as of the time of writing, it increased by 6.97%, reaching HKD 130.5, with a transaction volume of HKD 749 million.

In terms of news, according to AKESO's official WeChat account, on October 16, the results of the registrational Phase III clinical study (AK112-306/HARMONi-6) comparing the self-developed global first-in-class bispecific antibody drug Ivosidenib (PD-1/VEGF bispecific antibody) combined with chemotherapy against Tislelizumab combined with chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC) have been accepted by the prestigious international medical journal The Lancet and will be published during the European Society for Medical Oncology (ESMO 2025) conference in 2025, with significant results set to shine on the global scientific research stage.

It is reported that the research results have successfully been selected for the 2025 ESMO Late-Breaking Abstract (LBA) and will be presented in a verbal report at the most anticipated Presidential Symposium of the ESMO annual meeting by the principal investigator, Professor Lu Shun, Director of the Oncology Department at Shanghai Chest Hospital, showcasing the outstanding results of the head-to-head Phase III clinical study of Ivosidenib combined with chemotherapy versus the currently most widely used PD-1 combined chemotherapy regimen in tumor immunotherapy to the global oncology community

### Related Stocks

- [09926.HK - AKESO](https://longbridge.com/en/quote/09926.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 康方生物公司宣佈將在 2026 年美國臨牀腫瘤學會胃腸癌研討會上展示其真實世界研究成果 | 康方生物（Akeso, Inc.）宣佈將在 2026 年 ASCO GI 研討會上展示一項真實世界研究，比較卡多利單抗（cadonilimab）聯合化療與 PD-1 抑制劑聯合化療在晚期胃癌治療中的效果。結果顯示，卡多利單抗方案在總體生存期 | [Link](https://longbridge.com/en/news/272499977.md) |
| 康方生物報告 Cadonilimab 在一線 PD-L1 低表達胃癌研究中表現優於 PD-1 抑制劑 | 康方生物報告稱，卡多利單抗聯合化療在一項針對 PD-L1 CPS  | [Link](https://longbridge.com/en/news/272494568.md) |
| 長假期利好遊戲股 網易或符雙重主要上市標準 大行看好心動公司 | 長假期利好遊戲股，網易（9999）去年第四季盈利下滑，但股價已反映情況，適合撈底。心動公司（2400）中期盈利增長強勁。網易全年純利 337.6 億元，股東權益回報率 21%。網易有望符合港交所雙重主要上市標準，若成功將可納入滬深港通。新春 | [Link](https://longbridge.com/en/news/276402845.md) |
| 中國白銀集團 (0815) 折讓 18% 配股籌 4.6 億 | 中國白銀集團宣佈將向 6 名認購人發行 9.1 億股認購股份，折讓約 17.74%，每股認購價為 0.51 元，籌集資金總額為 4.641 億元。所得款項將用於日喀則礦的資本開支、進一步融資及一般營運資金。 | [Link](https://longbridge.com/en/news/276432450.md) |
| 川普宣佈即起調高全球關税至 15% 回應最高法院裁決 | 美國總統川普宣佈將進口至美國的全球性關税從 10% 提高至 15%，即刻生效。此舉是對最高法院推翻他先前廣泛關税措施的回應。川普在社交平台上表示，經過對最高法院裁決的檢視，政府決定將關税調升至法律允許的 15% 水平。 | [Link](https://longbridge.com/en/news/276518727.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.